Details
| Stereochemistry | MIXED |
| Molecular Formula | C21H27NO2 |
| Molecular Weight | 325.4446 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C(O)C1=CC=C(O)C=C1)N2CCC(CC3=CC=CC=C3)CC2
InChI
InChIKey=UYNVMODNBIQBMV-UHFFFAOYSA-N
InChI=1S/C21H27NO2/c1-16(21(24)19-7-9-20(23)10-8-19)22-13-11-18(12-14-22)15-17-5-3-2-4-6-17/h2-10,16,18,21,23-24H,11-15H2,1H3
| Molecular Formula | C21H27NO2 |
| Molecular Weight | 325.4446 |
| Charge | 0 |
| Count |
|
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11554553
http://en.pharmacodia.com/web/drug/1_11124.html
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/11554553
http://en.pharmacodia.com/web/drug/1_11124.html
Ifenprodil (marketed under the brands Vadilex; Dilvax; Creocral; Cerocral) is a selective NMDA receptor (glutamate) antagonist. Additionally, ifenprodil inhibits GIRK channels, and interacts with alpha1 adrenergic, serotonin, and sigma receptors. Ifenprodil acts as a vasodilator. Ifenprodil is a medicine available in a number of countries worldwide, but not in US.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1907603 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20692832 |
190.0 nM [IC50] | ||
Target ID: CHEMBL1904 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26912202 |
47.0 nM [IC50] | ||
Target ID: CHEMBL3465 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25704012 |
28.27 nM [IC50] | ||
Target ID: CHEMBL2094251 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08064 |
100.0 nM [IC50] | ||
Target ID: CHEMBL3038489 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16123769 |
7.01 µM [IC50] | ||
Target ID: CHEMBL3038488 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16123769 |
2.83 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Ifenprodil Approved UsePeripheral vascular disease |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
10.13 ng/mL |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.1 ng/mL |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
28.9 ng/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
20.4 ng/mL |
10 mg 1 times / day steady-state, intravenous dose: 10 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
21.7 ng × h/mL |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
41.3 ng × h/mL |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
63.1 ng × h/mL |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
47 ng × h/mL |
10 mg 1 times / day steady-state, intravenous dose: 10 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.87 h |
5 mg single, intravenous dose: 5 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3.61 h |
10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.07 h |
15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4.25 h |
10 mg 1 times / day steady-state, intravenous dose: 10 mg route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
IFENPRODIL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Chronic ethanol ingestion facilitates N-methyl-D-aspartate receptor function and expression in rat lateral/basolateral amygdala neurons. | 2003-12 |
|
| NMDA currents and receptor protein are downregulated in the amygdala during maintenance of fear memory. | 2003-11-12 |
|
| Fyn kinase and NR2B-containing NMDA receptors regulate acute ethanol sensitivity but not ethanol intake or conditioned reward. | 2003-11 |
|
| Acute dissociation for analyses of NMDA receptor function in cortical neurons during aging. | 2003-10-15 |
|
| Effect of the NR3 subunit on ethanol inhibition of recombinant NMDA receptors. | 2003-10-10 |
|
| Postsynaptic contributions to hippocampal network hyperexcitability induced by chronic activity blockade in vivo. | 2003-10 |
|
| Overexpression of spermidine/spermine N1-acetyltransferase elevates the threshold to pentylenetetrazol-induced seizure activity in transgenic mice. | 2003-10 |
|
| Effects of NMDA receptor antagonists on acute mu-opioid analgesia in the rat. | 2003-09 |
|
| The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. | 2003-08-29 |
|
| Polyamines in a genetic animal model of paroxysmal dyskinesia. | 2003-08-15 |
|
| Activation of NMDA receptors in rat dentate gyrus granule cells by spontaneous and evoked transmitter release. | 2003-08 |
|
| Development and subunit composition of synaptic NMDA receptors in the amygdala: NR2B synapses in the adult central amygdala. | 2003-07-30 |
|
| Enhanced GABA(A) receptor-mediated activity following activation of NMDA receptors in Cajal-Retzius cells in the developing mouse neocortex. | 2003-07-01 |
|
| Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? | 2003-07 |
|
| Polyamines contribute to ethanol withdrawal-induced neurotoxicity in rat hippocampal slice cultures through interactions with the NMDA receptor. | 2003-07 |
|
| Amphetamine-evoked c-fos mRNA expression in the caudate-putamen: the effects of DA and NMDA receptor antagonists vary as a function of neuronal phenotype and environmental context. | 2003-07 |
|
| Behavioral effects of NMDA receptor agonists and antagonists in combination with nitric oxide-related compounds. | 2003-06-20 |
|
| Lack of ifenprodil anxiolytic activity after its multiple treatment in chronically ethanol-treated rats. | 2003-06-20 |
|
| ATP inhibits NMDA receptors after heterologous expression and in cultured hippocampal neurons and attenuates NMDA-mediated neurotoxicity. | 2003-06-15 |
|
| NR2B and NR2D subunits coassemble in cerebellar Golgi cells to form a distinct NMDA receptor subtype restricted to extrasynaptic sites. | 2003-06-15 |
|
| N-Methyl-D-aspartate receptors contribute to the maintenance of dopaminergic neurons in rat midbrain slice cultures. | 2003-05-01 |
|
| NMDA-receptor antagonism via dextromethorphan and ifenprodil modulates graded anxiety test performance of C57BL/6 mice. | 2003-05 |
|
| Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine. | 2003-05 |
|
| Involvement of voltage- and ligand-gated Ca2+ channels in the neuroexcitatory and synergistic effects of putative uremic neurotoxins. | 2003-05 |
|
| Expression of behavioral sensitization to ethanol by DBA/2J mice: the role of NMDA and non-NMDA glutamate receptors. | 2003-05 |
|
| Functional NMDA receptor subtype 2B is expressed in astrocytes after ischemia in vivo and anoxia in vitro. | 2003-04-15 |
|
| Contribution of NR2B subunits to synaptic transmission in amygdaloid interneurons. | 2003-04-01 |
|
| PSD-95 regulates NMDA receptors in developing cerebellar granule neurons of the rat. | 2003-04-01 |
|
| Excitatory synaptic transmission in the lateral and central amygdala. | 2003-04 |
|
| Lithium-induced inhibition of Src tyrosine kinase in rat cerebral cortical neurons: a role in neuroprotection against N-methyl-D-aspartate receptor-mediated excitotoxicity. | 2003-03-13 |
|
| Ionotropic glutamate receptors: still a target for neuroprotection in brain ischemia? Insights from in vitro studies. | 2003-02 |
|
| Excitatory amino acid receptors of the electrosensory system: the NR1/NR2B N-methyl-D-aspartate receptor. | 2003-02 |
|
| Evidence for functionally distinct synaptic NMDA receptors in ventromedial versus dorsolateral striatum. | 2003-01 |
|
| Comparison of effect of ethanol on N-methyl-D-aspartate- and GABA-gated currents from acutely dissociated neurons: absence of regional differences in sensitivity to ethanol. | 2003-01 |
|
| Differential alterations in the expression of NMDA receptor subunits following chronic ethanol treatment in primary cultures of rat cortical and hippocampal neurones. | 2003-01 |
|
| Ionotropic and metabotropic glutamate receptor mediation of glucocorticoid-induced apoptosis in hippocampal cells and the neuroprotective role of synaptic N-methyl-D-aspartate receptors. | 2003 |
|
| Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists. | 2003 |
|
| Developmental Pb2+ exposure alters NMDAR subtypes and reduces CREB phosphorylation in the rat brain. | 2002-12-15 |
|
| Expression of functional NR1/NR2B-type NMDA receptors in neuronally differentiated SK-N-SH human cell line. | 2002-12 |
|
| Ethanol sensitivity of NMDA receptors. | 2002-12 |
|
| Radioligand binding studies reveal agmatine is a more selective antagonist for a polyamine-site on the NMDA receptor than arcaine or ifenprodil. | 2002-10-11 |
|
| Intrathecally administered big dynorphin, a prodynorphin-derived peptide, produces nociceptive behavior through an N-methyl-D-aspartate receptor mechanism. | 2002-10-11 |
|
| Acamprosate, MK-801, and ifenprodil inhibit neurotoxicity and calcium entry induced by ethanol withdrawal in organotypic slice cultures from neonatal rat hippocampus. | 2002-10 |
|
| Changes in the effect of isoflurane on N-methyl-D-aspartic acid-gated currents in cultured cerebral cortical neurons with time in culture: evidence for subunit specificity. | 2002-10 |
|
| Resistance to alcohol withdrawal-induced behaviour in Fyn transgenic mice and its reversal by ifenprodil. | 2002-09-30 |
|
| Selective NR2B NMDA receptor antagonists are protective against staurosporine-induced apoptosis. | 2002-09-27 |
|
| Site-selective N-methyl-D-aspartate and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonists produce distinct effects in rats performing complex discriminations. | 2002-09 |
|
| Differential regulation of synaptic and extra-synaptic NMDA receptors. | 2002-09 |
|
| Effects of acamprosate and some polyamine site ligands of NMDA receptor on short-term memory in rats. | 2002-05-24 |
|
| [Effects of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propanol (ifenprodil) on the cardiovascular system in vivo]. | 1975-09 |
Sample Use Guides
Oral
Peripheral vascular disease
Adult: As tartrate: 40-60 mg daily.
Injection
Peripheral vascular disease
Adult: As tartrate: Up to 15 mg daily by deep IM or slow IV Inj or IV infusion.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10747189
Ifenprodil (10 uM) reduced whole-cell NMDA-evoked currents by approximately 80 % in Golgi cells of the rat cerebellum..
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:44:22 GMT 2025
by
admin
on
Mon Mar 31 18:44:22 GMT 2025
|
| Record UNII |
R8OE3P6O5S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QC04AX28
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
||
|
FDA ORPHAN DRUG |
914122
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
||
|
WHO-ATC |
C04AX28
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
||
|
NCI_THESAURUS |
C29713
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB08123MIG
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
23210-56-2
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
3236
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
CHEMBL305187
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
3689
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
27403
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
1419
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
100000083680
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
C010739
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
C83782
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
IFENPRODIL
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
245-491-4
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
DTXSID2045656
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
R8OE3P6O5S
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
DB08954
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | |||
|
m6206
Created by
admin on Mon Mar 31 18:44:22 GMT 2025 , Edited by admin on Mon Mar 31 18:44:22 GMT 2025
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |